Melagatran/ximelagatran versus enoxaparin for the prevention of venous thromboembolic events - EXTEND
Study identifier:D4003C00030
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
The "EXTEND" study: A randomized, double-blind, parallel-group, phase III b, multi-centre study evaluating extended prophylactic treatment with melagatran/ximelagatran versus enoxaparin for the prevention of venous thromboembolic events in patients undergoing elective hip replacement or hip fracture surgery.
Medical condition
Thromboembolism
Phase
Phase 3
Healthy volunteers
No
Study drug
EXANTA
Sex
All
Actual Enrollment
3300
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2005
Primary Completion Date: 01 Aug 2006
Study Completion Date: 01 Aug 2006
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verification:
Verified 01 Nov 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Medical Science Director
AstraZeneca
